One-Day Agenda
Sessions
Partner Slots
Breaks & Admin
Opening Presentation
Closing the Human Biology Gap: Building More Predictive Preclinical Models
- Improving the human relevance of preclinical models for better translation
- Using organoids, human tissues, 3D models and advanced in vitro systems to capture disease biology
- Identifying where current models fail and how next-generation approaches can improve prediction
Keynote Presentation
New Modalities, New Challenges: What Does It Take to Build a Clinically Viable Medicine?
- Translating emerging modalities from scientific promise into viable therapeutic candidates
- Addressing challenges in efficacy, selectivity, delivery, safety and manufacturability
- Understanding what differentiates promising new modalities from clinically viable medicines
TBC
Presentation 1
AI in Drug Discovery: From Prediction to Experimental Validation
- Applying AI and machine learning to target identification, molecular design and drug discovery decisions
- Moving beyond computational predictions toward experimentally validated results
- Integrating AI with biological data and laboratory workflows to improve discovery efficiency
TBC
Deep Dive Session
The Lead Optimization Challenge: Balancing Potency, Selectivity, Exposure & Developability
- Optimising potency and selectivity without compromising pharmacokinetic properties
- Managing ADME, exposure and physicochemical liabilities during lead optimisation
- Making better candidate-selection decisions through multiparameter optimisation
TBC
Problem Solution Matrix
Predicting Human Safety Earlier: Why Preclinical Safety Signals Still Fail to Protect Clinical Programs
- Understanding why preclinical safety findings do not always predict human outcomes
- Improving early identification of toxicity and safety liabilities
- Integrating translational models and safety data into earlier development decisions
Presentation 2
AI + Human Expertise: Where Should We Trust Algorithms—and Where Do Scientists Still Need to Lead?
- Defining where AI can enhance scientific decision-making and where human judgement remains essential
- Managing model uncertainty, bias and explainability in drug discovery
- Building effective human–AI workflows that combine computational speed with scientific expertise
TBC
Strategic Discussion
Crossing the Biotech Valley of Death: De-Risking Early Programs for the Next Investment Milestone
- Identifying the scientific and development risks that prevent promising programmes from progressing
- Building stronger evidence packages to reach the next funding or development milestone
- Aligning scientific validation, development strategy and investor expectations to improve programme success
Presentation 3
Target Validation in Complex Biology: From Biological Association to Therapeutic Confidence
- Moving from genetic and biological associations to functional evidence of target relevance
- Strengthening target validation across disease models and biological contexts
- Improving confidence in target selection before major discovery investment
TBC
Panel Discussion
Can We Make Drug Discovery Faster, Smarter & More Predictable?
- Where current drug discovery workflows create unnecessary delays, cost and uncertainty
- How better collaboration, data integration and decision-making can improve R&D productivity
- What the industry needs to change to move promising programs forward with greater confidence